GlassScriptPhysician profile
Christopher R Cromwell
NPI 1629073382
$3,457.71
in general payments reported to CMS, 2019-2025
24 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $362 · 2021: $644 · 2022: $177 · 2023: $60.91 · 2024: $789 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129 · Long Term Medical Supply Or Device Loan: $543 · Travel and Lodging: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.80 |
| Long Term Medical Supply Or Device Loan | $543.48 |
| Travel and Lodging | $349.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $929.76 | 2025 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Sientra, INC. | $543.54 | 2021-2022 | |
| Kerecis Limited | $376.97 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Abbvie INC. | $301.75 | 2019-2025 | Skyrizi |
| Tela Bio, INC. | $242.44 | 2021-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Boston Scientific Corporation | $146.16 | 2024 | Spyglass Discover |
| Regeneron Healthcare Solutions, INC. | $134.29 | 2019-2021 | |
| Mentor Worldwide LLC | $117.30 | 2022-2024 | Artoura Breast Tissue Expander, Mentor Memorygel Resterilizable Gel Sizer |
| Allergan, INC. | $113.35 | 2020 | |
| Musculoskeletal Transplant Foundation INC. | $111.27 | 2019-2025 | |
| Janssen Biotech, INC. | $65.07 | 2020-2021 | |
| Leo Pharma INC. | $49.82 | 2021 | |
| Organogenesis INC. | $47.95 | 2019-2022 | |
| Ucb, INC. | $38.26 | 2021 | |
| Triad Life Sciences INC. | $37.08 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $36.76 | 2020 | |
| Axogen | $36.34 | 2019 | |
| Sun Pharmaceutical Industries INC. | $33.68 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $20.04 | 2019 | |
| Janssen Scientific Affairs, LLC | $19.71 | 2019 | |
| Acell, INC. | $19.14 | 2020 | |
| Galderma Laboratories, L.P. | $16.59 | 2019 | |
| Vyne Pharmaceuticals INC. | $15.86 | 2020 | |
| Amniox Medical, INC. | $4.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cromwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.